-
公开(公告)号：EP4342993A1
公开(公告)日：2024-03-27
申请号：EP22804725.4
申请日：2022-05-18
IPC分类号： C12N15/88 , A61K9/10 , A61K9/14 , A61K31/7088 , A61K31/7115 , A61K39/12 , A61K47/18 , A61K47/24 , A61K47/28 , A61K47/34 , A61K48/00 , A61P11/00 , A61P15/00 , A61P31/20 , A61P37/04 , C12N15/34
摘要： Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and/or treating infection with human papillomavirus type 6 and/or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.
[In the formula, R 1 , R 2 , p, L 1 and L 2 are as defined in the specification.]-
公开(公告)号：EP4342491A1
公开(公告)日：2024-03-27
申请号：EP22804712.2
申请日：2022-05-18
申请人： National Institutes of Biomedical Innovation, Health and Nutrition , University of The Ryukyus , Daiichi Sankyo Company, Limited
发明人： ISHII Ken , FUKUSHIMA Takuya , TANAKA Yuetsu , TAKESHITA Fumihiko , KOIZUMI Makoto , NIWA Takako , NOGUSA Shoko , JONAI Nao , ONODERA Yoshikuni
IPC分类号： A61K39/21 , A61K9/127 , A61K31/7115 , A61K38/16 , A61K47/10 , A61K47/18 , A61K47/24 , A61K47/28 , A61P31/14 , C12N15/88
摘要： Provided is a vaccine for preventing and/or treating infection with human T-cell leukemia virus type 1 (HTLV-1).
A lipid particle encapsulating a nucleic acid expressing a gp46 antigen or a Tax antigen of human T-cell leukemia virus type 1 (HTLV-1), wherein the lipid comprises a cationic lipid represented by general formula (Ia):
or a pharmaceutically acceptable salt thereof,
wherein
R 1 and R 2 each independently represent a C 1 -C 3 alkyl group;
L 1 represents a C 17 -C 19 alkenyl group optionally having one or more C 2 -C 4 alkanoyloxy groups;
L 2 represents a C 10 -C 19 alkyl group optionally having one or more C 2 -C 4 alkanoyloxy groups, or a C 10 -C 19 alkenyl group optionally having one or more C 2 -C 4 alkanoyloxy groups; and
p is 3 or 4.-
公开(公告)号：EP4253546A2
公开(公告)日：2023-10-04
申请号：EP23176351.7
申请日：2014-09-19
申请人： National Institutes of Biomedical Innovation, Health and Nutrition , Daiichi Sankyo Company, Limited
发明人： ISHII, Ken , KOBIYAMA, Kouji , AOSHI, Taiki , TAKESHITA, Fumihiko , KASUYA, Yuji , NIWA, Takako , KOIZUMI, Makoto
IPC分类号： C12N15/117
摘要： The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3'-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and β-1,3-glucan.
-
公开(公告)号：EP4245763A1
公开(公告)日：2023-09-20
申请号：EP21891898.5
申请日：2021-11-10
IPC分类号： C07H15/04 , A61K39/12 , A61K39/145 , A61K39/165 , A61K39/20 , A61K39/215 , A61K39/235 , A61K39/35 , A61K39/36 , A61K39/39 , A61P31/04 , A61P31/12 , A61P31/16 , A61P33/02 , A61P37/08 , A61P39/02
摘要： The present invention provides a novel compound or a pharmaceutically acceptable salt thereof which has a TLR4 activating effect and can be used as an immunostimulant or an adjuvant in vaccines or allergen immunotherapy. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In this context, X, Y, Z and n in the formula (I) are each as defined herein.
-
公开(公告)号：EP4212552A1
公开(公告)日：2023-07-19
申请号：EP22198821.5
申请日：2015-01-28
发明人： NAITO, Hiroyuki , OGITANI, Yusuke , MASUDA, Takeshi , NAKADA, Takashi , YOSHIDA, Masao , ASHIDA, Shinji , MORITA, Koji , MIYAZAKI, Hideki , KASUYA, Yuji , HAYAKAWA, Ichiro , ABE, Yuki
IPC分类号： C07K16/28 , A61K31/4745 , A61K39/395 , A61P35/00 , C07D491/052
摘要： As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L 1 -L 2 -L P -NH-(CH 2 )n 1 -L a -(CH 2 )n 2 -C(=O)- wherein the anti-HER2 antibody is connected to the terminal L 1 , and the antitumor compound is connected to the carbonyl group of the -(CH 2 )n 2 -C(=O)-moiety with the nitrogen atom of the amino group at position 1 as the connecting position:
-
公开(公告)号：EP4171651A1
公开(公告)日：2023-05-03
申请号：EP21736709.3
申请日：2021-06-23
发明人： METTETAL II, Jerome Thomas , DURANT, Stephen Thomas , ASTANEH, Azadeh Cheraghchi Bashi , LAU, Alan Yin Kai , WALLEZ, Yann
IPC分类号： A61K47/68 , A61K31/4745 , A61K45/06 , A61P35/00
-
公开(公告)号：EP4171650A1
公开(公告)日：2023-05-03
申请号：EP21736708.5
申请日：2021-06-23
发明人： METTETAL II, Jerome Thomas , DURANT, Stephen Thomas , ASTANEH, Azadeh Cheraghchi Bashi , LAU, Alan Yin Kai , WALLEZ, Yann
IPC分类号： A61K47/68 , A61K31/5377 , A61K45/06 , A61P35/00
-
公开(公告)号：EP4166158A1
公开(公告)日：2023-04-19
申请号：EP21821552.3
申请日：2021-06-10
发明人： KAWAOKA, Yoshihiro , IMAI, Masaki , YAMAYOSHI, Seiya , ISHII, Ken , KOBIYAMA, Kouji , NAMBA, Eiko , OKA, Tatsuya , TOZUKA, Miyuki , JONAI, Nao , ONODERA, Yoshikuni , TAKESHITA, Fumihiko , SUZUKI, Takashi , NIWA, Takako , KOIZUMI, Makoto , NAKAMURA, Kensuke
IPC分类号： A61K39/00 , A61K39/215 , A61K48/00 , A61P31/12 , A61P31/14 , C07K14/165 , A61K9/107 , A61K9/14 , A61K47/14 , A61K47/18 , A61K47/24 , A61K47/28 , C12N15/50 , C12N15/88 , A61K31/7105
摘要： The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof
wherein R 1 and R 2 each independently represent a C 1 -C 3 alkyl group;
L 1 represents a C 17 -C 19 alkenyl group which may have one or a plurality of C 2 -C 4 alkanoyloxy groups;
L 2 represents a C 10 -C 19 alkyl group which may have one or a plurality of C 2 -C 4 alkanoyloxy groups or a C 10 -C 19 alkenyl group which may have one or a plurality of C 2 -C 4 alkanoyloxy groups; and
p is 3 or 4.-
公开(公告)号：EP4026537A1
公开(公告)日：2022-07-13
申请号：EP22158818.9
申请日：2015-11-05
发明人： Endo, Yoko , Takahashi, Kyohei , Umezaki, Shinya
IPC分类号： A61K9/08 , A61K47/02 , A61K47/10 , A61K47/18 , A61K31/5383 , A61K31/573 , A61P27/02 , A61P29/00 , A61P31/04
摘要： The present invention relates to an ophthalmic aqueous composition comprising levofloxacin, a salt thereof, or a solvate thereof; phosphate ester of dexamethasone, or a salt of the phosphate ester of dexamethasone; one or at least two isotonic agents; and benzalkonium chloride.
-
公开(公告)号：EP3973995A1
公开(公告)日：2022-03-30
申请号：EP21187152.0
申请日：2015-01-28
发明人： NAITO, Hiroyuki , OGITANI, Yusuke , MASUDA, Takeshi , NAKADA, Takashi , YOSHIDA, Masao , ASHIDA, Shinji , MORITA, Koji , MIYAZAKI, Hideki , KASUYA, Yuji , HAYAKAWA, Ichiro , ABE, Yuki
摘要： As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: ―L 1 ―L 2 ―L P ―NH― (CH 2 ) n 1 ―L a ― (CH 2 ) n 2 ― C(=O)― wherein the anti-HER2 antibody is connected to the terminal L 1 , and the antitumor compound is connected to the carbonyl group of the - (CH 2 )n 2 ―C(=0) ― moiety with the nitrogen atom of the amino group at position 1 as the connecting position:
-
-
-
-
-
-
-
-
-
搜索结果
1647 条记录 (耗时 0.018 秒)
